Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: Recommendations for clinical practice
Palomero-Gallagher N, Hoffstaedter F, Mohlberg H, Eickhoff SB, Amunts K, Zilles K
10.1042/BSR20110046 Biosci
Glucagon-like peptide type 1 receptor agonistsIncretin effect and systemic effects of glucagon-like peptide type 1 and its agonists The incretin effect describes the phenomenon whereby oral glucose elicits higher (23 times) insulin secretory responses than does intravenous glucose.25 This is due to incretin hormones, such as GLP-1 or glucose-dependent insulinotropic polypeptide, which stimulate insulin secretion in response to food intake
These effects almost always resolve within a few weeks as your body adjusts
In-Network Providers and Standard Treatment Plans Choosing in-network providers who follow evidence-based protocols also increases the chance of coverage